Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)

CLJ. Weinstein, P. Sliwinska-Stanczyk, T. Hála, M. Stanislav, A. Tzontcheva, R. Yao, Y. Berd, SP. Curtis, G. Philip

. 2023 ; 62 (11) : 3601-3609. [pub] 2023Nov02

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000754

OBJECTIVES: The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in. METHODS: Eligible participants received OL GLM in period 1. In period 2, participants who achieved inactive disease were randomized 1:1:1 to receive double-blind (DB) treatment with monthly placebo (PBO, treatment withdrawal) or continued GLM treatment given monthly (GLM QMT) or every 2 months (GLM Q2MT). Participants who did not have a disease flare continued DB treatment for ∼12 months. Participants with a disease flare discontinued DB treatment and resumed monthly OL GLM. Primary endpoint compared the proportion of participants without a disease flare in the continued GLM treatment groups (QMT or Q2MT) vs PBO in a multiplicity-controlled, step-down fashion. Safety follow-up continued for ∼3 months after last treatment. RESULTS: A total of 188 patients, out of the 323 enrolled, were eligible for participation in period 2. Both GLM QMT and GLM Q2MT were superior to treatment withdrawal (PBO) in preventing disease flare (P < 0.001), with a treatment-difference vs PBO of 50.4% and 34.4% for the GLM QMT and GLM Q2MT groups, respectively. The time-to-first flare was significantly longer (log-rank P < 0.0001) with GLM treatment compared with PBO. Of 53 participants (in Q2MT or PBO) who had a confirmed disease flare, 51 (96.2%) attained a clinical response within 3 months of restarting OL GLM. Adverse events were consistent with the known GLM safety profile. CONCLUSION: Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017.).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000754
003      
CZ-PrNML
005      
20240213093346.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/kead112 $2 doi
035    __
$a (PubMed)36919768
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Weinstein, Cindy L J $u Merck & Co., Inc., Rahway, NJ, USA $1 https://orcid.org/0000000342294644
245    10
$a Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK) / $c CLJ. Weinstein, P. Sliwinska-Stanczyk, T. Hála, M. Stanislav, A. Tzontcheva, R. Yao, Y. Berd, SP. Curtis, G. Philip
520    9_
$a OBJECTIVES: The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in. METHODS: Eligible participants received OL GLM in period 1. In period 2, participants who achieved inactive disease were randomized 1:1:1 to receive double-blind (DB) treatment with monthly placebo (PBO, treatment withdrawal) or continued GLM treatment given monthly (GLM QMT) or every 2 months (GLM Q2MT). Participants who did not have a disease flare continued DB treatment for ∼12 months. Participants with a disease flare discontinued DB treatment and resumed monthly OL GLM. Primary endpoint compared the proportion of participants without a disease flare in the continued GLM treatment groups (QMT or Q2MT) vs PBO in a multiplicity-controlled, step-down fashion. Safety follow-up continued for ∼3 months after last treatment. RESULTS: A total of 188 patients, out of the 323 enrolled, were eligible for participation in period 2. Both GLM QMT and GLM Q2MT were superior to treatment withdrawal (PBO) in preventing disease flare (P < 0.001), with a treatment-difference vs PBO of 50.4% and 34.4% for the GLM QMT and GLM Q2MT groups, respectively. The time-to-first flare was significantly longer (log-rank P < 0.0001) with GLM treatment compared with PBO. Of 53 participants (in Q2MT or PBO) who had a confirmed disease flare, 51 (96.2%) attained a clinical response within 3 months of restarting OL GLM. Adverse events were consistent with the known GLM safety profile. CONCLUSION: Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017.).
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a non-radiografická axiální spondyloartritida $7 D000089202
650    _2
$a syndrom vzplanutí nemoci $7 D000067251
650    _2
$a výsledek terapie $7 D016896
650    _2
$a opakovaná terapie $7 D019233
650    _2
$a dvojitá slepá metoda $7 D004311
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sliwinska-Stanczyk, Paula $u Reumatika Centrum Reumatologii, Warsaw, Poland
700    1_
$a Hála, Tomas $u CCR Czech a.s., Pardubice, Czech Republic
700    1_
$a Stanislav, Marina $u Vladimirsky Moscow Regional Scientific Institution, Moscow, Russia
700    1_
$a Tzontcheva, Anjela $u MSD, Zurich, Switzerland
700    1_
$a Yao, Ruji $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Berd, Yuliya $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Curtis, Sean P $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Philip, George $u Merck & Co., Inc., Rahway, NJ, USA $1 https://orcid.org/0000000239067232
773    0_
$w MED00011379 $t Rheumatology $x 1462-0332 $g Roč. 62, č. 11 (2023), s. 3601-3609
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36919768 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093343 $b ABA008
999    __
$a ok $b bmc $g 2049403 $s 1210448
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 11 $d 3601-3609 $e 2023Nov02 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace